A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections

被引:45
|
作者
Nitta, Hiroaki [1 ]
Kelly, Brian D. [2 ]
Padilla, Mary [3 ]
Wick, Nikolaus [4 ]
Brunhoeber, Patrick [5 ]
Bai, Isaac [6 ]
Singh, Shalini [5 ]
Ranger-Moore, Jim [6 ]
Bieniarz, Chris [2 ]
Tsuda, Hitoshi [7 ]
Grogan, Thomas M. [1 ]
机构
[1] Ventana Med Syst Inc, Med Innovat, Tucson, AZ USA
[2] Ventana Med Syst Inc, Technol & Appl Res, Tucson, AZ USA
[3] Roche Diagnost SL, Roche Tissue Diagnost, Barcelona, Spain
[4] Ventana Med Syst Inc, Sci Affairs, Tucson, AZ USA
[5] Ventana Med Syst Inc, Med Affairs, Tucson, AZ USA
[6] Ventana Med Syst Inc, Biostat & Data Management, Tucson, AZ USA
[7] Natl Canc Ctr, Dept Pathol, Tokyo, Japan
关键词
Gene-protein assay; Dual color in situ hybridization; Immunohistochemistry; HER2; Breast cancer; IN-SITU HYBRIDIZATION; ADJUVANT TRASTUZUMAB; IMMUNOHISTOCHEMISTRY; EXPRESSION; HER-2/NEU; BENZIDINE; SINGLE;
D O I
10.1186/1746-1596-7-60
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: The eligibility of breast cancer patients for human epidermal growth factor receptor 2 (HER2)-directed therapies is determined by the HER2 gene amplification and/or HER2 protein overexpression status of the breast tumor as determined by in situ hybridization (ISH) or immunohistochemistry (IHC), respectively. Our objective was to combine the US Food and Drug Administration (FDA)-approved HER2 & chromosome 17 centromere (CEN17) brightfield ISH (BISH) and HER2 IHC assays into a single automated HER2 gene-protein assay allowing simultaneous detection of all three targets in a single tissue section. Methods: The HER2 gene-protein assay was optimized using formalin-fixed, paraffin-embedded (FFPE) samples of the xenograft tumors MCF7 [HER2 negative (non-amplified gene, protein negative)] and Calu-3 [HER2 positive (amplified gene, protein positive)]. HER2 IHC was performed using a rabbit monoclonal anti-HER2 antibody (clone 4B5) and a conventional 3,3'-diaminobenzidine IHC detection. The HER2 & CEN17 BISH signals were visualized using horseradish peroxidase-based silver and alkaline phosphatase-based red detection systems, respectively with a cocktail of 2,4-dinitrophenyl-labeled HER2 and digoxigenin-labeled CEN17 probes. The performance of the gene-protein assay on tissue microarray slides containing 189 randomly selected FFPE clinical breast cancer tissue cores was compared to that of the separate HER2 IHC and HER2 & CEN17 BISH assays. Results: HER2 protein detection was optimal when the HER2 IHC protocol was used before (rather than after) the BISH protocol. The sequential use of HER2 IHC and HER2 & CEN17 BISH detection steps on FFPE xenograft tumor sections appropriately co-localized the HER2 protein, HER2 gene, and CEN17 signals after mitigating the silver background staining by using a naphthol phosphate-containing hybridization buffer for the hybridization step. The HER2 protein and HER2 gene status obtained using the multiplex HER2 gene-protein assay demonstrated high concordance with those obtained using the separate HER2 IHC and HER2 & CEN17 BISH assays, respectively. Conclusions: We have developed a protocol that allows simultaneous visualization of the HER2 IHC and HER2 & CEN17 BISH targets. This automated protocol facilitated the determination of HER2 protein and HER2 gene status in randomly selected breast cancer samples, particularly in cases that were equivocal or exhibited tumor heterogeneity. The HER2 gene-protein assay produced results virtually equivalent to those of the single FDA-approved HER2 IHC and HER2 & CEN17 BISH assays. Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2041964038705297
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Assessments of HER2 Gene Status in Breast Carcinomas with Polysomy of Chromosome 17
    Gatalica, Z.
    Repertinger, S.
    Hatcher, L.
    Ulmer, P.
    MODERN PATHOLOGY, 2009, 22 : 41A - 41A
  • [42] Assessments of HER2 Gene Status in Breast Carcinomas with Polysomy of Chromosome 17
    Gatalica, Z.
    Repertinger, S.
    Hatcher, L.
    Ulmer, P.
    LABORATORY INVESTIGATION, 2009, 89 : 41A - 41A
  • [43] Droplet Digital PCR Measurement of HER2 Copy Number Alteration in Formalin-Fixed Paraffin-Embedded Breast Carcinoma Tissue
    Belgrader, Phillip
    Tanner, Stephanie C.
    Regan, John F.
    Koehler, Ryan
    Hindson, Benjamin J.
    Brown, Alexandra S.
    CLINICAL CHEMISTRY, 2013, 59 (06) : 991 - 994
  • [44] Protocol for HER2 FISH determination on PAXgene-fixed and paraffin-embedded tissue in breast cancer
    Oberauner-Wappis, Lisa
    Loibner, Martina
    Viertler, Christian
    Groelz, Daniel
    Wyrich, Ralf
    Zatloukal, Kurt
    INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2016, 97 (02) : 202 - 206
  • [45] Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry
    Davies, Vanessa
    Voutsadakis, Ioannis A.
    CANCER INVESTIGATION, 2020, 38 (02) : 94 - 101
  • [46] Methodology matters - prognostic significance of HER2 protein expression versus HER2 gene amplification in metastatic breast cancer
    Todorovic-Rakovic, N.
    Jovanovic, D.
    Neskovic-Konstantinovic, Z.
    Nikolic-Vukosavljevic, D.
    EJC SUPPLEMENTS, 2008, 6 (09): : 160 - 160
  • [47] Gene protein detection platform: An automated technique of combined immunohistochemistry and Brightfield double in situ hybridization in the Context of HER2 protein, gene and chromosome 17-centromere evaluations for breast cancer
    Farrajota, P.
    Olsson, A.
    Elmberger, G.
    VIRCHOWS ARCHIV, 2012, 461 : S165 - S165
  • [48] Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 g ene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH)
    Hiroaki Nitta
    Beatrice Hauss-Wegrzyniak
    Megan Lehrkamp
    Adrian E Murillo
    Fabien Gaire
    Michael Farrell
    Eric Walk
    Frederique Penault-Llorca
    Masafumi Kurosumi
    Manfred Dietel
    Lin Wang
    Margaret Loftus
    James Pettay
    Raymond R Tubbs
    Thomas M Grogan
    Diagnostic Pathology, 3
  • [49] HER2 gene amplification association with protein expression in equivocal (HER2 IHC 2+) breast carcinomas: consequences of cell-by-cell analysis on HER2 gen protein assay (GPA) slides
    Pekar, G.
    VIRCHOWS ARCHIV, 2019, 475 : S75 - S76
  • [50] Incidence and Significance of Fluorescent In Situ Hybridization (FISH) HER2 Gene Amplification by HER2 Gene Copy Number of ≥ 6.0 with Her2/CEP17 Ratio of <2.0 in Breast Cancer
    Apple, Sophia
    LABORATORY INVESTIGATION, 2017, 97 : 29A - 30A